Alzheimer's Disease and the Eye |
Autore | Weiss Jeffrey N |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cham : , : Springer, , 2024 |
Descrizione fisica | 1 online resource (146 pages) |
ISBN |
9783031588112
9783031588105 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910869167603321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Clinical Trials in Age-Related Macular Degeneration Treatment |
Autore | Weiss Jeffrey N |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
Descrizione fisica | 1 online resource (300 pages) |
ISBN |
9783031588037
9783031588020 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Introduction to Age-Related Macular Degeneration -- Further Reading -- Chapter 2: Tables -- Chapter 3: Stem Cell Studies -- United States -- Recruiting -- Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-Related Macular Degeneration (AMD) -- ClinicalTrials.gov ID NCT04627428 -- United States -- Recruiting -- Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated with Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT04339764 -- United States -- Recruiting -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- United States -- Recruiting -- A Study of the Safety and Tolerability of ASP7317 in Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT03178149 -- Caribbean -- Recruiting -- Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases -- ClinicalTrials.gov ID NCT05147701 -- China -- Not Yet Recruiting -- Preparation of Patient Autologous-Induced Pluripotent Stem Cell-Derived Retinal Cells for AMD -- ClinicalTrials.gov ID NCT05991986 -- China -- Recruiting -- Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration -- ClinicalTrials.gov ID NCT05445063 -- Great Britain -- Recruiting -- A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT01691261 -- Great Britain -- Not Yet Recruiting -- Retinal Pigment Epithelium Safety Study for Patients in B4711001 -- ClinicalTrials.gov ID NCT03102138 -- Chapter 4: Gene Therapy Trials -- United States.
Not Yet Recruiting -- Phase I/II Study of SKG0106 Intraocular Solution in Patients with Neovascular Age-Related Macular Degeneration (nAMD) -- ClinicalTrials.gov ID NCT05986864 -- United States -- Recruiting -- 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05197270 -- United States -- Recruiting -- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants with Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) -- ClinicalTrials.gov ID NCT04514653 -- United States -- Recruiting -- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients with Neovascular Age-Related Macular Degeneration [LUNA] -- ClinicalTrials.gov ID NCT05536973 -- United States -- Recruiting -- A Study of EXG102-031 in Patients with wAMD (Everest) -- ClinicalTrials.gov ID NCT05903794 -- United States -- Recruiting -- Pivotal 2 Study of RGX-314 Gene Therapy in Participants with nAMD (ASCENT) -- ClinicalTrials.gov ID NCT05407636 -- United States -- Recruiting -- Pivotal 1 Study of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE) -- ClinicalTrials.gov ID NCT04704921 -- Canada -- Recruiting -- NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05984927 -- China -- Recruiting -- Safety and Tolerability of KH631 Gene Therapy in Participants with Neovascular Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05657301 -- China -- Recruiting -- Safety and Tolerability of KH631 Gene Therapy in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) -- ClinicalTrials.gov ID NCT05672121 -- China -- Not Yet Recruiting -- Gene Therapy for Wet AMD -- ClinicalTrials.gov ID NCT05611424 -- China -- Recruiting -- CRISPR/Cas13-Mediated RNA Targeting Therapy for the Treatment of nAMD Investigator-Initiated Trial (SIGHT-I). ClinicalTrials.gov ID NCT06031727 -- China -- Recruiting -- VEGFA-Targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases -- ClinicalTrials.gov ID NCT05099094 -- China -- Not Yet Recruiting -- An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients with nAMD -- ClinicalTrials.gov ID NCT06022744 -- Chapter 5: Other Trials -- United States -- Recruiting -- Microcurrent Stimulation Therapy for Nonexudative Age-Related Macular Degeneration (i-SIGHT) -- ClinicalTrials.gov ID NCT05447650 -- United States -- Recruiting -- A Masked, Placebo-Controlled Study to Assess Iptacopan in Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05230537 -- United States -- Recruiting -- Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD) -- ClinicalTrials.gov ID NCT05893537 -- United States -- Recruiting -- Evaluation of OLX10212 in Patients with Neovascular Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05643118 -- United States -- Recruiting -- Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (ODYSSEY) -- ClinicalTrials.gov ID NCT05891548 -- United States -- Recruiting -- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients with Neovascular Age-Related Macular Degeneration [LUNA] -- ClinicalTrials.gov ID NCT05536973 -- United States -- Recruiting -- Study of Zifibancimig in Participants with Neovascular Age-Related Macular Degeneration (BURGUNDY) -- ClinicalTrials.gov ID NCT04567303 -- United States -- Not Yet Recruiting -- Non-invasive Ultrasound Retinal Stimulation for Vision Restoration -- ClinicalTrials.gov ID NCT05914233 -- United States -- Recruiting. A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05626114 -- United States -- Recruiting -- Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHOENIX) -- ClinicalTrials.gov ID NCT05949593 -- Australia -- Not Yet Recruiting -- Safety of BBC1501 Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration (nAMD) -- ClinicalTrials.gov ID NCT05803785 -- Australia -- Recruiting -- Subthreshold Laser Treatment in Intermediate Age-Related Macular Degeneration with Nascent Geographic Atrophy Study (LIANA) -- ClinicalTrials.gov ID NCT05200624 -- Austria -- Recruiting -- Faricimab for High-Frequent Aflibercept Treated Neovascular Age-Related Macular Degeneration (FAN) -- ClinicalTrials.gov ID NCT05941715 -- Austria -- Recruiting -- Therapy of Age-Related Macular Degeneration (MET) -- ClinicalTrials.gov ID NCT05222997 -- China -- Not Yet Recruiting -- A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-Related Macular Degeneration (wAMD) -- ClinicalTrials.gov ID NCT04572698 -- China -- Recruiting -- Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with wAMD -- ClinicalTrials.gov ID NCT05003245 -- China -- Recruiting -- A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with wAMD -- ClinicalTrials.gov ID NCT04740671 -- China -- Recruiting -- Treatment of Recalcitrant Neovascular AMD Using Brolocizumab with Immediate T& -- E -- ClinicalTrials.gov ID NCT05710471 -- China -- Recruiting -- Study of IBI333 in Subjects with Neovascular Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05639530 -- China -- Recruiting. QA108 Phase II Study in Subjects with Intermediate Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05562219 -- Italy -- Recruiting -- Photobiomodulation in Dry Age-Related Macular Degeneration (DRUSEN) -- ClinicalTrials.gov ID NCT06046118 -- Korea -- Recruiting -- Study of Application of Transcutaneous Pulsed Electrical Stimulation Around Eye in Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05259371 -- Norway -- Not Yet Recruiting -- Photobiomodulation for Dry Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT05507840 -- South America -- Recruiting -- OcuDyne System in the Treatment of AMD -- ClinicalTrials.gov ID NCT05091476 -- Thailand -- Recruiting -- A Study to Investigate the Effect on Central Macular Thickness of Treatment with MG-O-1002 Eye Drops in Participants Aged over 45 with Neovascular Age-Related Macular Degeneration (nAMD) -- ClinicalTrials.gov ID NCT05390840 -- Index. |
Record Nr. | UNINA-9910872187903321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer International Publishing AG, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Clinical Trials in Optic Nerve Disease Treatment |
Autore | Weiss Jeffrey N |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cham : , : Springer, , 2024 |
Descrizione fisica | 1 online resource (337 pages) |
ISBN |
9783031588150
9783031588143 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Introduction to Optic Nerve Disease -- Further Reading -- Chapter 2: Stem Cell Studies in Optic Nerve Disease Treatment -- Recruiting -- United States -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Recruiting -- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases -- ClinicalTrials.gov ID NCT00716066 -- Recruiting -- Neurologic Stem Cell Treatment Study (NEST) -- ClinicalTrials.gov ID NCT02795052 -- Recruiting -- Caribbean/South America -- Safety of Cultured Allogeneic Adult Umbilical Cord-Derived Mesenchymal Stem Cells for Eye Diseases -- ClinicalTrials.gov ID NCT05147701 -- Completed -- United States -- Hematopoietic Stem Cell Transplant in Devic's Disease -- ClinicalTrials.gov ID NCT00787722 -- Completed -- China -- Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders -- ClinicalTrials.gov ID NCT02249676 -- Completed -- Turkey -- Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells with Electromagnetic Stimulation (Magnovision) -- ClinicalTrials.gov ID NCT04877067 -- Completed -- United Kingdom -- Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) -- ClinicalTrials.gov ID NCT00395200 -- Terminated -- Canada -- Reason: Recruitment Failure -- Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (SCT-NMO) -- ClinicalTrials.gov ID NCT01339455 -- Withdrawn -- United States -- Reason: Discontinued by Investigator -- Autologous Transplant to End NMO Spectrum Disorder (ATTEND) -- ClinicalTrials.gov ID NCT03829566 -- Unknown Status -- China -- Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Progressive Multiple Sclerosis and Neuromyelitis Optica -- ClinicalTrials.gov ID NCT01364246 -- Unknown Status -- India.
Study the Safety and Efficacy of Bone Marrow-Derived Autologous Cells for the Treatment of Optic Nerve Disease (OND) -- ClinicalTrials.gov ID NCT01834079 -- Unknown Status -- Jordan -- Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells -- ClinicalTrials.gov ID NCT02638714 -- Unknown Status -- Russian Federation -- Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration -- ClinicalTrials.gov ID NCT02144103 -- Unknown Status -- Spain -- Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NEUROSTEM) -- ClinicalTrials.gov ID NCT03173638 -- Chapter 3: Gene Therapy Studies in Optic Nerve Disease Treatment -- Recruiting -- China -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy (GOLD) -- ClinicalTrials.gov ID NCT04912843 -- Recruiting -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated with ND1 Mutations -- ClinicalTrials.gov ID NCT05820152 -- Completed -- United States/Europe -- RESCUE and REVERSE Long-Term Follow-Up (RESTORE) -- ClinicalTrials.gov ID NCT03406104 -- Completed -- Efficacy Study of GS010 for Treatment of Vision Loss from 7 Months to 1 Year from Onset in LHON Due to the ND4 Mutation (REVERSE) (REVERSE) -- ClinicalTrials.gov ID NCT02652780 -- Completed -- Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months from Onset in LHON Due to the ND4 Mutation (RESCUE) -- ClinicalTrials.gov ID NCT02652767 -- Completed -- China -- Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (rAAV2-ND4) -- ClinicalTrials.gov ID NCT01267422 -- Completed -- France -- Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients. ClinicalTrials.gov ID NCT02064569 -- Not Yet Recruiting -- No Location -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated with ND4 Mutations -- ClinicalTrials.gov ID NCT05293626 -- Active, Not Recruiting -- United States/Europe -- Safety Study of an Adeno-Associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) -- ClinicalTrials.gov ID NCT02161380 -- Active, Not Recruiting -- Efficacy & -- Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT) -- ClinicalTrials.gov ID NCT03293524 -- Active, Not Recruiting -- China -- A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy -- ClinicalTrials.gov ID NCT03153293 -- Unknown Status -- China -- Efficacy Study of Gene Therapy for the Treatment of Acute LHON Onset Within Three Months (LHON) -- ClinicalTrials.gov ID NCT03428178 -- Chapter 4: Other Treatment Studies for Optic Nerve Disease -- Recruiting -- United States -- Electrical Stimulation for the Treatment of Optic Neuropathies (rtACS) -- ClinicalTrials.gov ID NCT05626426 -- Recruiting -- China -- Targeted Shortwave Diathermy Combined with Perceptual Training for Patients with Severe Traumatic Optic Neuropathy -- ClinicalTrials.gov ID NCT05140486 -- Completed -- United States -- Vision Restoration Therapy (VRT) to Treat Non-arteritic Anterior Ischemic OpticNeuropathy -- ClinicalTrials.gov ID NCT00140491 -- Completed -- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Ampyra) -- ClinicalTrials.gov ID NCT01975324 -- Completed -- Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION) -- ClinicalTrials.gov ID NCT00561834 -- Completed. A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy -- ClinicalTrials.gov ID NCT02693119 -- Completed -- Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS) -- ClinicalTrials.gov ID NCT02774005 -- Completed -- Lipoic Acid as a Treatment for Acute Optic Neuritis -- ClinicalTrials.gov ID NCT01294176 -- Completed -- Single Oral Doses Study of Nerispirdine on Visual Function in Patients with Multiple Sclerosis -- ClinicalTrials.gov ID NCT00772525 -- Completed -- Intravenous Immunoglobulin Therapy in Optic Neuritis -- ClinicalTrials.gov ID NCT00000117 -- Completed -- A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) -- ClinicalTrials.gov ID NCT00304291 -- Completed -- Efficacy and Safety Study of Satralizumab (SA237) as Add-On Therapy to Treat Participants with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) -- ClinicalTrials.gov ID NCT02028884 -- Completed -- Ampyra for Optic Neuritis in Multiple Sclerosis -- ClinicalTrials.gov ID NCT01337986 -- Completed -- Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) -- ClinicalTrials.gov ID NCT02073279 -- Completed -- Europe -- Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT optnerve) -- ClinicalTrials.gov ID NCT01280877 -- Completed -- Trial of Alternating Current Stimulation in Optic Neuropathy (SCT Optnerve) -- ClinicalTrials.gov ID NCT01270126 -- Completed -- Citicoline in Non-arteritic Ischemic Optic Neuropathy -- ClinicalTrials.gov ID NCT03758118 -- Completed -- Middle East -- Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2). ClinicalTrials.gov ID NCT03308448 -- Terminated -- United States -- Near-Infrared Light-Emitting Diode (NIR-LED) Therapy for Leber's -- Hereditary Opticneuropathy (LHON) (LHON) -- ClinicalTrials.gov ID NCT01389817 -- Unknown Status -- Middle East -- NAION Treatment with Oral Prednisolone and Erythropoietin Injection (NAION) -- ClinicalTrials.gov ID NCT03715881 -- Unknown Status -- Spain -- Intravenous Infusion of Prostaglandins as Therapy in Patients with Anterior Non-arteritic Ischemic Optic Neuropathy (PG-NAION) -- ClinicalTrials.gov ID NCT03851562 -- Chapter 5: Addendum: Hereditary Optic Neuropathies -- Leber's Hereditary Optic Neuropathy -- Nonarteritic Ischemic Optic Neuropathy (NAION) -- Neuromyelitis Optica (NMO, Devic's Disease) -- Index. |
Record Nr. | UNINA-9910872181903321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Clinical Trials in Retinitis Pigmentosa Treatment / / by Jeffrey N. Weiss |
Autore | Weiss Jeffrey N |
Edizione | [1st ed. 2024.] |
Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
Descrizione fisica | 1 online resource (281 pages) |
Disciplina | 617.7 |
Soggetto topico | Ophthalmology |
ISBN |
9783031587993
9783031587986 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Part 1: Introduction -- Chapter 1. Introduction to Retinitis Pigmentosa -- Chapter 2. Treatments -- Chapter 3. Notes -- Part 2: Completed Clinical Trials -- Chapter 4. United States -- Chapter 5. Brazil -- Chapter 6. Turkey -- Part 3: Active, Recruiting Clinical Trials -- Chapter 7. United States -- Chapter 8. Latin America -- Chapter 9. Turkey -- Part 4: Not Yet Recruiting Clinical Trials -- Chapter 10. Indonesia -- Part 5: Active, Not Recruiting -- Chapter 11. United States -- Chapter 12. France -- Part 6: Enrolling by Invitation -- Chapter 13. United States -- Chapter 14. Indonesia -- Part 7: Gene Therapy Studies -- Chapter 15. United States/Europe -- Chapter 16. India -- Chapter 17. Saudi Arabia -- Part 8: Active, Recruiting Gene Therapy Studies -- Chapter 18. United States -- Chapter 19. China -- Part 9: Active, Not Recruiting Gene Therapy Studies -- Chapter 20. United States -- Chapter 21. Germany -- Chapter 22. Sweden -- Part 10: Enrolling by Invitation Gene Therapy Studies -- Chapter 23. Americas/Europe -- Chapter 24. India -- Part 11: Optogenetics -- Chapter 25. Active Trials in United States -- Part 12: Other Treatments -- Chapter 26. Completed Trials in The Americas/Europe -- Chapter 27. Completed Trials in China -- Chapter 28. Completed Trials in Italy -- Chapter 29. Completed Trials in Turkey -- Chapter 30. Active Trials in the United States -- Chapter 31. Active Trials in Australia -- Chapter 32. Active Trials in China -- Chapter 33. Active, Not Recruiting Trials in the US/Europe -- Chapter 34. Not Yet Recruiting Trials in China. |
Record Nr. | UNINA-9910881086803321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Clinical Trials in Stargardt Disease Treatment |
Autore | Weiss Jeffrey N |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
Descrizione fisica | 1 online resource (240 pages) |
ISBN |
9783031588075
9783031588068 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Introduction to Stargardt Disease -- Further Reading -- Chapter 2: Tables -- Chapter 3: Recruiting Studies -- Recruiting -- United States -- Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian) -- ClinicalTrials.gov ID NCT05956626 -- United States -- Recruiting -- Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT02402660 -- United States -- Recruiting -- Rod- and Cone-Mediated Function in Retinal Disease -- ClinicalTrials.gov ID NCT02617966 -- United States -- Recruiting -- Stargardt-Like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 -- ClinicalTrials.gov ID NCT04591483 -- United States -- Recruiting -- Oral Metformin for Treatment of ABCA4 Retinopathy -- ClinicalTrials.gov ID NCT04545736 -- United States -- Recruiting -- Genotype-Phenotype Study of Patients with Plaquenil-Induced Retinal Toxicity, with Evaluation of the ABCA4 Gene -- ClinicalTrials.gov ID NCT01145196 -- United States -- Recruiting -- Inherited Retinal Degenerative Disease Registry (MRTR) -- ClinicalTrials.gov ID NCT02435940 -- United States -- Recruiting -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Spain -- Recruiting -- Structural and Functional Characterization of Rare Ocular Diseases (RADIS) -- ClinicalTrials.gov ID NCT05258032 -- Switzerland -- Recruiting -- Function and Imaging Assessments for G1961E-associated Stargardt Disease (FIRSTORBIT) -- ClinicalTrials.gov ID NCT05674058 -- Chapter 4: Enrolling by Invitation Studies -- United States -- Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study (SUSTAIN) -- ClinicalTrials.gov ID NCT06048185 -- United States -- Enrolling by Invitation.
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT04239625 -- Chapter 5: Active, Not Recruiting Studies -- United States -- Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01736592 -- United States -- Active, Not Recruiting -- Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Stargardt Disease (STARLIGHT) -- ClinicalTrials.gov ID NCT05417126 -- United States -- Active, Not Recruiting -- Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects with STGD1 (DRAGON) -- ClinicalTrials.gov ID NCT05244304 -- United States -- Active, Not Recruiting -- Zimura Compared to Sham in Patients with Autosomal Recessive Stargardt Disease (STGD1) -- ClinicalTrials.gov ID NCT03364153 -- United States -- Active, Not Recruiting -- Natural History of Eye Diseases Related to ABCA4 Mutations -- ClinicalTrials.gov ID NCT01736293 -- Australia -- Active, Not Recruiting -- This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT05266014 -- Chapter 6: Completed Studies -- United States -- The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy (ProgStar-4) -- ClinicalTrials.gov ID NCT02410122 -- No Results Posted -- United States -- Completed -- Safety and Efficacy of Emixustat in Stargardt Disease (SeaSTAR) -- ClinicalTrials.gov ID NCT03772665 -- Results -- Outcome Measures -- United States -- Completed. A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies (ProgSTAR) -- ClinicalTrials.gov ID NCT01977846 -- Results -- Outcome Measures -- United States -- Completed -- Study of STG-001 in Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT04489511 -- United States -- Completed -- DHA Supplementation in Patients With STGD3 -- ClinicalTrials.gov ID NCT00420602 -- No Results Posted -- United States -- Completed -- Pharmacodynamic Study of Emixustat Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease -- ClinicalTrials.gov ID NCT03033108 -- Results -- Outcome Measures -- United States -- Completed -- Microcurrent Stimulation to Treat Macular Degeneration -- ClinicalTrials.gov ID NCT01790958 -- United States -- Completed -- Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy -- ClinicalTrials.gov ID NCT00346853 -- United States -- Completed -- Effect of DHA Supplements on Macular Function in Patients with Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy -- ClinicalTrials.gov ID NCT00060749 -- United States -- Completed -- Long-Term Follow-Up of Subretinal Transplantation of hESC-Derived RPE Cells in Stargardt Macular Dystrophy Patients -- ClinicalTrials.gov ID NCT02445612 -- United States -- Completed -- Subretinal Transplantation of hESC-Derived RPE(MA09-hRPE)Cells in Patients with Stargardt's Macular Dystrophy -- ClinicalTrials.gov ID NCT01345006 -- Brazil -- Completed -- Stem Cell Therapy for Outer Retinal Degenerations -- ClinicalTrials.gov ID NCT02903576 -- China -- Completed -- The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients with Maculopathies -- ClinicalTrials.gov ID NCT05904444 -- Columbia -- Completed -- Efficacy of Acupuncture in Macular Diseases (AMAD) -- ClinicalTrials.gov ID NCT02255981 -- Results. Outcome Measures -- Europe -- Completed -- Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (MADEOS) -- ClinicalTrials.gov ID NCT03297515 -- Europe -- Completed -- Pupil Dynamics and Color Vision for the Detection of Eye Diseases (PupDyn) -- ClinicalTrials.gov ID NCT04909398 -- United Kingdom -- Completed -- A Follow-Up Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT02941991 -- United Kingdom -- Completed -- Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01469832 -- No Location -- Completed -- Phase 1 Safety Study of ALK-001 in Healthy Volunteers -- ClinicalTrials.gov ID NCT02230228 -- Chapter 7: Terminated Studies -- United States -- Phase I/IIA Study of SAR422459 in Participants with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01367444 -- Results -- Outcome Measures -- United States -- Terminated -- Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease -- ClinicalTrials.gov ID NCT01676766 -- United States -- Terminated -- Oxidative Stress in Stargardt Disease, Age-Related Macular Degeneration, and Diabetic Retinopathy -- ClinicalTrials.gov ID NCT02875704 -- Chapter 8: Unknown Status Studies -- China -- Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell-Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases -- ClinicalTrials.gov ID NCT02749734 -- Europe -- Unknown Status -- Saffron Supplementation in Stargardt's Disease (STARSAF02). ClinicalTrials.gov ID NCT01278277 -- Europe -- Unknown Status -- Stem Cells Therapy in Degenerative Diseases of the Retina -- ClinicalTrials.gov ID NCT03772938 -- Korea -- Unknown Status -- Safety and Tolerability of MA09-hRPE Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01625559 -- United Kingdom -- Unknown Status -- Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those with Severely Reduced Vision -- ClinicalTrials.gov ID NCT04281732 -- Index. |
Record Nr. | UNINA-9910872187303321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer International Publishing AG, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Ocular Stem Cell Studies : A Comprehensive Overview of Global Clinical Trials |
Autore | Weiss Jeffrey N |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Cham : , : Springer, , 2024 |
Descrizione fisica | 1 online resource (364 pages) |
ISBN |
9783031585579
9783031585562 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Preface -- Contents -- Chapter 1: Active/Recruiting Ocular Stem Cell Studies -- United States -- Retina/Optic Nerve -- Recruiting -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Recruiting -- Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy (iPSC) -- ClinicalTrials.gov ID NCT03403699 -- Recruiting -- CNS10-NPC for the Treatment of RP -- ClinicalTrials.gov ID NCT04284293 -- Recruiting -- Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration (AMD) -- ClinicalTrials.gov ID NCT04627428 -- Recruiting -- Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT04339764 -- Enrolling By Invitation -- Clinical Trial of Autologous Intravitreal Bone-Marrow CD34+ Stem Cells for Retinopathy -- ClinicalTrials.gov ID NCT01736059 -- Chapter 2: Active, Not Recruiting Ocular Stem Cell Studies -- Safety and Tolerability of hRPC in Retinitis Pigmentosa (hRPCRP) -- ClinicalTrials.gov ID NCT02464436 -- Belarus -- Enrolling by Invitation -- Treatment of Age-Related Macular Degeneration Using Retinal Stem and Progenitor Cells -- ClinicalTrials.gov ID NCT05187104 -- Caribbean/Argentina/Mexico -- Recruiting -- Safety of Cultured Allogeneic Adult Umbilical Cord-Derived Mesenchymal Stem Cells for Eye Diseases -- ClinicalTrials.gov ID NCT05147701 -- China -- Recruiting -- Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration -- ClinicalTrials.gov ID NCT05445063 -- Great Britain -- Recruiting -- A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age-Related Macular Degeneration.
ClinicalTrials.gov ID NCT01691261 -- Indonesia -- Not Yet Recruiting -- Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase II/III -- ClinicalTrials.gov ID NCT05909488 -- Japan -- Recruiting -- Clinical Study of PAL-222 Targeting Patients with Myopic Chorioretinal Atrophy (PAMyCA) -- ClinicalTrials.gov ID NCT05658237 -- Turkey -- Recruiting -- The Effect of Stem Cells and Stem Cell Exosomes on Visual Functions in Patients With Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT05413148 -- United States: Anterior Segment -- Not Yet Recruiting -- Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells -- ClinicalTrials.gov ID NCT05705024 -- Recruiting -- Stem Cell Therapy for Limbal Stem Cell Deficiency -- ClinicalTrials.gov ID NCT03957954 -- Canada -- Recruiting -- Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency (CECA) -- ClinicalTrials.gov ID NCT01756365 -- China -- Not Yet Recruiting -- Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post-Refractive Surgery and Associated With Blepharospasm -- ClinicalTrials.gov ID NCT05738629 -- Recruiting -- Effect of UMSCs Derived Exosomes on Dry Eye in Patients with cGVHD -- ClinicalTrials.gov ID NCT04213248 -- Not Yet Recruiting -- Therapeutic Effect of Stem Cell Eye Drops on Dry Eye Disease -- ClinicalTrials.gov ID NCT05784519 -- France -- Recruiting -- Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency (FEMJA) -- ClinicalTrials.gov ID NCT03949881 -- Spain -- Not Yet Recruiting -- Cultivated Limbal Epithelial Transplantation (CLET) for Limbal Stem Cell Deficiency (LSCD) (CLET-4-LSCD) -- ClinicalTrials.gov ID NCT03884569 -- United States/Australia/Brazil/Canada/Egypt. Active, Not Recruiting -- Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma -- ClinicalTrials.gov ID NCT00554788 -- Active, Not Recruiting -- Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa (BMSCRP1) -- ClinicalTrials.gov ID NCT04925687 -- Active, Not Recruiting -- Treatment of Central Retinal Vein Occlusion Using Stem Cell Study (TRUST) -- ClinicalTrials.gov ID NCT03981549 -- Active, Not Recruiting -- Safety and Tolerability of hRPC in Retinitis Pigmentosa (hRPCRP) -- ClinicalTrials.gov ID NCT02464436 -- No Location -- Active, Not Recruiting -- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration -- ClinicalTrials.gov ID NCT02286089 -- Anterior Segment -- United States -- Active, Not Recruiting -- Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft (CALEC) -- ClinicalTrials.gov ID NCT02592330 -- Active, Not Recruiting -- United States/Germany -- Allogeneic ABCB5-Positive Limbal Stem Cells for Treatment of LSCD -- ClinicalTrials.gov ID NCT03549299 -- Denmark -- Active, Not Recruiting -- Treatment with Allogeneic Adipose-Derived Mesenchymal Stem Cells in Patients with Aqueous Deficient Dry Eye Disease (MESADDE) -- ClinicalTrials.gov ID NCT03878628 -- France -- Active, Not Recruiting -- Interventional Study of Implantation of hESC-Derived RPE in Patients with RP Due to Monogenic Mutation -- ClinicalTrials.gov ID NCT03963154 -- Spain -- Active, Not Recruiting -- Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients with Cicatricial Conjunctivitis (CELOPHIN) -- ClinicalTrials.gov ID NCT05520086 -- Chapter 3: Completed Ocular Stem Cell Studies -- Retina/Optic Nerve -- United States. Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT04604899 -- Completed -- Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT03073733 -- Completed -- Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT02320812 -- Completed -- Hematopoietic Stem Cell Transplant in Devic's Disease -- ClinicalTrials.gov ID NCT00787722 -- Completed -- Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) -- ClinicalTrials.gov ID NCT01632527 -- Brazil -- Completed -- Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa (RETICELL) -- ClinicalTrials.gov ID NCT01560715 -- Completed -- Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT01068561 -- Completed -- Stem Cell Therapy for Outer Retinal Degenerations -- ClinicalTrials.gov ID NCT02903576 -- Turkey -- Completed -- Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa -- ClinicalTrials.gov ID NCT05712148 -- Completed -- Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation (Magnovision) -- ClinicalTrials.gov ID NCT04877067 -- Anterior Segment -- United States -- Completed -- Corneal Epithelial Stem Cells and Dry Eye Disease -- ClinicalTrials.gov ID NCT03302273 -- Belarus -- Completed -- Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells -- ClinicalTrials.gov ID NCT04484402 -- Iran -- Completed. The Improvement of Limbal Stem Cell Deficiency (LSCD) in Unilateral Stem Cell Damage by Amniotic Membrane Extract Eye Drop (AMEED) -- ClinicalTrials.gov ID NCT02649621 -- Completed -- Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients -- ClinicalTrials.gov ID NCT00736307 -- Korea -- Completed -- Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency -- ClinicalTrials.gov ID NCT04773431 -- Spain -- Completed -- Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome -- ClinicalTrials.gov ID NCT01562002 -- Completed -- Autologous Adipose-Derived Adult Stem Cell Implantation for Corneal Diseases (ADASCs-CT-CD) (ADASCs-CT-CD) -- ClinicalTrials.gov ID NCT05279157 -- Chapter 4: Unknown Status Ocular Stem Cell Studies -- Belgium -- Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial (MLEC) -- ClinicalTrials.gov ID NCT02318485 -- Unknown Status -- Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency (LECT) -- ClinicalTrials.gov ID NCT00845117 -- Brazil -- Unknown Status -- Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy (RetinaCell) -- ClinicalTrials.gov ID NCT01518842 -- China -- Unknown Status -- MSC-Exos Promote Healing of MHs (MSCs) -- ClinicalTrials.gov ID NCT03437759 -- Unknown Status -- Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell-Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases -- ClinicalTrials.gov ID NCT02749734 -- Unknown Status -- Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn -- ClinicalTrials.gov ID NCT03237442 -- Unknown Status -- Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) -- ClinicalTrials.gov ID NCT00953485 -- Unknown Status. Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Progressive Multiple Sclerosis and Neuromyelitis Optica. |
Record Nr. | UNINA-9910872190903321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer, , 2024 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Physician Crisis : Why Physicians Are Leaving Medicine, Why You Should Stay, and How To Be Happy / / by Jeffrey N. Weiss |
Autore | Weiss Jeffrey N |
Edizione | [1st ed. 2023.] |
Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
Descrizione fisica | 1 online resource (109 pages) |
Disciplina | 610.695023 |
Soggetto topico |
Medicine
Clinical Medicine |
Soggetto non controllato |
Medicine
Medical |
ISBN |
9783031279799
9783031279782 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Chapter 1. The Nature of the Problem -- Chapter 2. Getting into Medical School -- Chapter 3. Financing Medical School -- Chapter 4. Medical School Curriculum -- Chapter 5. Post Medical School Graduate Training -- Chapter 6. Jobs -- Chapter 7. Electronic Medical Records (EMR) -- Chapter 8. Physician “Burnout” -- Chapter 9. Getting Paid – Medicare/Medicaid/Private Insurance Companies -- Chapter 10. What are the Customer Experience Challenges in Healthcare? -- Chapter 11. Drug Pricing -- Chapter 12. “Malpractice” -- Chapter 13. Hospital Employment -- Chapter14. Private Equity -- Chapter 15. What Country has the Best Healthcare? -- Chapter 16. Health Insurance Portability and Accountability Act (HIPAA) -- Chapter 17. Political Influence -- Chapter 18. Possible Solutions -- Chapter 19. Summary. . |
Record Nr. | UNINA-9910725096903321 |
Weiss Jeffrey N
![]() |
||
Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|